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Abstract Patients with Parkinson’s disease receive
selective irreversible monoamine oxidase (MAO)-B inhib-
itors, but their effects on MAO-A activity are not known
during long-term application. We determined MAO-A
inhibition in plasma samples from patients with MAO-B
inhibitor intake or without MAO-B inhibitor treatment and
from healthy controls. We detected a 70 % reduction of
MAO-A activity in patients with MAO-B inhibitor therapy
in comparison to the other groups. Our results suggest that
treatment with MAO-B inhibitor may also influence MAO-
A activity in vivo, when administered daily.
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Introduction
Treatment with selective monoamine oxidase (MAO)-B
inhibitors (MAO-B-Is) such as selegiline and rasagiline is
common in patients with Parkinson’s disease (PD)
(Deftereos et al. 2012). Two isoforms of the enzyme,
MAO-A and MAO-B, are known according to MAO (EC
1.4.3.4) substrate and inhibitor specificities (Johnston
1968). MAO-A is primarily located in the periphery with
approximately 80 % of total MAO activity in the gastro-
intestinal tract, lung and placenta. MAO-B is the major
isoform in the brain, blood platelets and abundant in the
basal ganglia (Collins and Youdim 1970). Serotonin
(5-HT), noradrenaline, adrenaline, dopamine as well as
b-phenylethylamine are major MAO substrates. Loss of
dopamine, noradrenaline and 5-HT is one essential bio-
chemical indicator of the neurodegenerative process in PD
(Bernheimer et al. 1973). In order to prolong the duration
of action of L-Dopa, inhibitors of L-Dopa decarboxylation
(Birkmayer and Mentasti 1967) as well as inhibitors of
MAO-B (Birkmayer et al. 1975) and COMT (Napolitano
et al. 1995) have been implemented in the treatment of PD.
To date, the effect of chronic MAO-B-I application on
MAO-A activity in humans is not well known. Results of a
PET study showed that daily oral 10 mg selegiline
administration inhibited MAO-A after 28 days in the stri-
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study, we investigated the impact of repeated MAO-B-Is
application on MAO-A enzyme activity in plasma of PD
patients for the first time.
Materials and methods
Collection of plasma samples
Plasma samples from PD patients treated with MAO-B-
Is, from PD patients without MAO-B-Is and from heal-
thy controls (clinical characteristics see Table 1) were
isolated from 10 ml EDTA blood. Blood samples were
taken at 11 am, 4 h after the oral intake of rasagiline or
selegiline. The blood was stored on ice and after cen-
trifugation the plasma fraction was aspirated and stored
at -80 C.
Determination of MAO-A enzyme activity
MAO-A enzyme activity was measured using MAO-GloTM
Assay (#V1401, Promega, Mannheim, Germany), which
provides a homogeneous luminescent method for MAO-A.
12.5 ll of plasma was diluted in specific MAO-A reaction
buffer and added to each well containing 120 lU of MAO-
A enzyme (#V1452, Promega, Mannheim, Germany). No
additional selegiline (Sigma Aldrich, Schnelldorf,
Germany) was added to the wells with plasma samples
collected from patients. The control experiment was per-
formed with standardized plasma (Sigma Aldrich, Sch-
nelldorf, Germany) with different doses of selegiline
(10 nM–10 mM) to determine IC50. Positive controls
contained no plasma and no selegiline, only the MAO-A
enzyme. The protocol was done according to the manual
(Promega, Germany), just the incubation time was adapted
to 50 min at 37 C. The end measurement was carried out
in a fluorescence multi plates meter at an excitation
wavelength of 542 nm and an emission of 590 nm.
Statistical analysis
Groups were compared by one-way analysis of variance
(ANOVA) in combination with the post hoc Scheffe´ Test
and p \ 0.05 was considered as significant. We normalized
the results by subtracting the plasma quench effect from
raw data and converted the data into percentages. The
MAO-A enzyme activity without plasma and selegiline has
been set at 100 % and the healthy control group (no PD)
was set at 100 % (Fig. 1). The presented results were
calculated against MAO-A activity or healthy controls, and
represent at least three repeated experiments with four
internal repeats.
Legal issues and ethical conduct
All subjects gave written informed consent. An indepen-
dent local institutional review board approved this study.
The open observational study was advertised according to
§ 4 Abs. 23 Satz 3 AMG at the medical association.
Results
Plasma samples taken from PD patients treated with
MAO-B-Is showed a reduction of more than 70 % of the
MAO-A enzyme activity compared to patient samples
without MAO-B-Is therapy and healthy controls (Fig. 1a).
Owing to the fluorometric-based assay and the high
concentration of plasma proteins, which may divert the
emitted light, the plasma samples quenched the MAO-A
activity in general (-64 %) (Fig. 1b). We took this effect
into account, but could still demonstrate a distinct decline
of MAO-A activity in the MAO-B-Is-treated patients
(Fig. 1a). There were no differences between rasagiline-
and selegiline-treated PD patients (Fig. 1a). Gender and
age had no influence on MAO-A activity (data not
shown). In addition, the direct effects of selegiline on
MAO-A activity were tested in vitro (Fig. 1b). After
incubating the human control standardized plasma sam-
ples (obtained from Sigma Aldrich) with 10 lM selegiline
or higher doses, the MAO-A enzyme activity decreased
(12–30 %) compared to a negative control (H2O). In this
experiment, the IC50 of selegiline was determined at
44 lM (data not shown) for MAO-A. So far the IC50 of
selegiline was determined just for MAO-B at 8 nM (Saura
et al. 1992).
Table 1 Demographic data of Parkinson’s disease (PD) patients and
controls
MAO-B-Is-
treated PD
patients
No MAO-B-
Is-treated PD
patients
Healthy
controls
Age (years; MW ± STD) 66 (±7) 73 (±6) 66 (±14)
Gender (f/m) 12/12 6/6 3/6
Treatment (rasagiline/
selegiline)
16/8 – –
Treatment duration (days;
MW ± STD)
167.5
(±271)
– –
Doses Rasagiline/
selegiline
1 mg/5 mg – –
Total number 24 11 9
MAO-B-Is monoamine oxidase-B inhibitors, MW mean, STD standard
error of mean, mg milligram, m male, f female
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Fig. 1 a Monoamine oxidase-A (MAO-A) activity in plasma sam-
ples. Plasma samples of healthy controls and Parkinson’s disease (PD)
patients with and without MAO-B inhibitors (MAO-B-Is) treatment
were tested. The MAO-A enzyme activity was measured via MAO-
GloTM Assay. Procedure and measurement was done according to the
manual. The box plots show the sample minimum, lower quartile,
median, upper quartile and samples maximum of each investigated
group. Statistical analysis was done using one-way ANOVA with the
Scheffe´ Test for post hoc analysis and the measurement was repeated
four times with three internal repeats. The healthy controls (no PD)
were set as 100 % [absolute mean value = 1.631.030 ± 101.812
relative luminescent units (RLU)] and compared to PD patients
without MAO-B-Is (absolute mean value = 1.393.674 ± 178.485
RLU) and to PD patients with MAO-B-Is (absolute mean
value = 428.500 ± 37.200 RLU). Dashed lines indicate p \ 0.001.
Healthy controls, n = 9; PD patients without MAO-B-Is treatment,
n = 11; PD patients with MAO-B-Is treatment, n = 24. b Plasma
quenches assay signal of MAO-A activity. Control plasma samples
were incubated with different doses of selegiline and afterwards
measured via MAO-GloTM Assay. Procedure and measurement was
done according to the manual. Statistical analysis was done using one-
way ANOVA with post hoc Scheffe´ Test and the experiment was
repeated three times with three internal repeats. The statistical
analysis was done as a comparison of standard plasma without any
treatment to different selegiline doses. *p \ 0.05; **p \ 0.01; n = 3
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Discussion
For the first time, we could demonstrate a 70 % reduction
in MAO-A enzyme activity ex vivo in plasma from PD
patients treated with selective irreversible MAO-B-Is.
Pharmacokinetic considerations may partially explain these
results. The mean elimination half-life time (t1/2) of
selegiline is 1.5 h; the t1/2 of rasagiline is 1.0 h in controls
and 1.3 h in patients (Chen et al. 2007; Mahmood et al.
1995). A fourfold increase of t1/2 to 6.0 h was demon-
strated after chronic selegiline administration in a daily
dose of 10 mg (Mahmood 1997). Since we drew plasma
samples 4 h after MAO-B-Is intake, we hypothesize that
active drug in plasma was responsible for the described
MAO-A inhibition. Our findings are supported by experi-
mental studies in rats treated with 5 mg/kg selegiline orally
for 5 days. Animals were decapitated 2 h after the last
application. Bowel MAO-A and MAO-B inhibition was 84
and 85 %, respectively. Liver MAO-B inhibition was
92 %, while MAO-A was blocked by 32 %. In the brain
tissue, MAO-B inhibition was 92 % and MAO-A was
inhibited by 18 % (Magyar 2011). However, subcutane-
ously and thus first-pass effect circumventing application
of 5 mg/kg selegiline for 5 days inhibited bowel MAO-B at
80 % and MAO-A at 62 %, liver MAO-B at 91 % and
MAO-A at 34 %, while brain MAO-B was blocked by
99 % and MAO-A by 85 % (Magyar 2011). This study
clearly shows differences of MAO inhibition in the
peripheral and central nervous systems following MAO-B-
Is treatment, but is in line with the suggestion that
‘‘selective’’ MAO-B-Is inhibit MAO-A activity according
to dosage. This finding is supported by a PET study using
11C-clorgyline to assess MAO-A activity in individuals
with either high-dose orally integrated tablet selegiline
(ODT-S; Zelapar) compared to a transdermal formulation
of selegiline (EMSAM) (Fahn et al. 2011). The authors
demonstrated that ODT-S (10 mg/day) inhibits brain
MAO-A to a similar degree than EMSAM (6 mg/day)
(Fahn et al. 2011). These findings and those of Magyar
(2011) demonstrate that the selegiline concentration after
high oral doses or when administered subcutaneously or via
transdermal application is high enough to inhibit MAO-A
activity. Our study is in line with these findings and dem-
onstrates that the concentration of both, selegiline (5 mg/
daily) and rasagiline (1 mg/daily), in plasma 4 h after the
last application is high enough to inhibit MAO-A activity.
According to Magyar (2011), this effect is already seen
after short-term (5 days) treatment of rats. Therefore,
accumulation of selegiline or rasagiline or their metabolites
with putative MAO-A/B inhibiting properties may not
explain this effect. Since long-term treatment with selegi-
line increases the t1/2 of the drug (Mahmood 1997; Chen
et al. 2007), this may keep the concentration of the
inhibitor high enough to block MAO-A in addition to
MAO-B. Indeed, 70 % inhibition of MAO might be suffi-
cient to increase MAO-A substrate concentration (Green
et al. 1977). But this potential loss of MAO-B-Is specificity
does not have to be a clinical disadvantage. An inhibition
of both isoenzymes suggests reducing neurotransmitter
amine degradation, biosynthesis of ROS and other toxic
compounds (Riederer et al. 2004, 2007).
In conclusion, we showed that chronic MAO-B-I
application also inhibits MAO-A activity ex vivo and may
therefore affect both peripheral and brain MAO. However,
a better understanding of the regulatory mechanisms of
MAO-B-Is and further research on the role of MAO-A/-B
interactions in the pathology of neurodegenerative disor-
ders such as PD as well as in the clinical concepts of
‘‘disease modification’’ and neuroprotective capacity of
MAO-B-Is is warranted (Mousseau and Baker 2012; Jenner
and Langston 2011; Naoi et al. 2012).
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